Skip to Main Content

Paper Details

Whole-genome characterization of chemoresistant ovarian cancer.
Nature
1039
2015
BRCA1, BRCA1 or, BRCA1 promoter, BRCA2, BRCA2 mutations, CCNE1, HGSC, NF1, PTEN, Patients, RAD51B, RB1, germline DNA samples, high-grade serous ovarian cancer, molecular subtype, ovarian cancer, patients, platinum, promoter, tumour
Author NameAffiliation
Ann-Marie PatchInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Ann-Marie PatchInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Dariush Etemadmoghadam1] Peter MacCallum Cancer Centre, University of Melbourne, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology
Dariush Etemadmoghadam1] Peter MacCallum Cancer Centre, University of Melbourne, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology
Joshy George
Joshy George
Sian FeredayPeter MacCallum Cancer Centre
Sian FeredayPeter MacCallum Cancer Centre
Katia NonesInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Katia NonesInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Kathryn AlsopPeter MacCallum Cancer Centre
Kathryn AlsopPeter MacCallum Cancer Centre
Karin S KassahnInstitute for Molecular Bioscience, The University of Queensland
Huei San LeongPeter MacCallum Cancer Centre
George Au-YeungPeter MacCallum Cancer Centre
George Au-YeungPeter MacCallum Cancer Centre
Catherine J KennedyUniversity of Sydney at Westmead Millennium Institute, Westmead Hospital
Yoke-Eng ChiewUniversity of Sydney at Westmead Millennium Institute, Westmead Hospital
Paul HarnettCrown Princess Mary Cancer Centre and University of Sydney at Westmead Hospital
Nadia TraficantePeter MacCallum Cancer Centre
Nadia TraficantePeter MacCallum Cancer Centre
Joy HendleyPeter MacCallum Cancer Centre
Heather ThornePeter MacCallum Cancer Centre
J Lynn FinkInstitute for Molecular Bioscience, The University of Queensland
Ronny DrapkinDana-Farber Cancer Institute
Ronny DrapkinDana-Farber Cancer Institute
Euan A StronachOvarian Cancer Action Research Centre, Imperial College London
Robert BrownOvarian Cancer Action Research Centre, Imperial College London
Maria A DoylePeter MacCallum Cancer Centre
Ernst LengyelUniversity of Chicago
John V PearsonInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
John V PearsonInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Nicola WaddellInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Nicola WaddellInstitute for Molecular Bioscience, The University of Queensland, Australia [2] QIMR Berghofer Medical Research Institute
Anna DeFazioUniversity of Sydney at Westmead Millennium Institute, Westmead Hospital
Anna DeFazioUniversity of Sydney at Westmead Millennium Institute, Westmead Hospital
Sean M GrimmondInstitute for Molecular Bioscience, The University of Queensland, Australia [2] WolfsonWohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow
Sean M GrimmondInstitute for Molecular Bioscience, The University of Queensland, Australia [2] WolfsonWohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow
David D L Bowtell1] Peter MacCallum Cancer Centre, University of Melbourne, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, Australia [4] Ovarian Cancer Action Research Centre, Imperial College London
David D L Bowtell1] Peter MacCallum Cancer Centre, University of Melbourne, Australia [3] Sir Peter MacCallum Cancer Centre Department of Oncology, Australia [4] Ovarian Cancer Action Research Centre, Imperial College London
  • 1 - 40

Datasets